Table 2:
Diagnosis | Treatment | |||||
---|---|---|---|---|---|---|
Year of birth* | Children, %† | Risk, December v. January | Children, %† | Risk, December v. January | ||
RD (95% CI) | RR (95% CI)‡ | RD (95% CI) | RR (95% CI)‡ | |||
Boys | ||||||
1997–98 | 2.6 | 0.62 (0.30 to 0.95) | 1.30 (1.13 to 1.48) | 3.4 | 1.04 (0.67 to 1.41) | 1.39 (1.23 to 1.56) |
1998–99 | 2.6 | 0.91 (0.58 to 1.23) | 1.46 (1.28 to 1.68) | 3.2 | 0.97 (0.61 to 1.32) | 1.40 (1.24 to 1.59) |
1999–00 | 2.6 | 0.72 (0.40 to 1.04) | 1.36 (1.19 to 1.57) | 3.1 | 1.07 (0.72 to 1.42) | 1.47 (1.29 to 1.66) |
2000–01 | 2.5 | 0.45 (0.13 to 0.78) | 1.21 (1.06 to 1.39) | 3.1 | 0.88 (0.53 to 1.23) | 1.37 (1.21 to 1.55) |
2001–02 | 2.7 | 0.78 (0.44 to 1.11) | 1.36 (1.19 to 1.56) | 3.2 | 1.28 (0.92 to 1.64) | 1.56 (1.38 to 1.77) |
2002–03 | 3.0 | 0.77 (0.42 to 1.13) | 1.32 (1.16 to 1.49) | 3.3 | 1.25 (0.87 to 1.62) | 1.50 (1.33 to 1.70) |
2003–04 | 3.2 | 0.75 (0.37 to 1.12) | 1.27 (1.13 to 1.43) | 3.5 | 1.02 (0.63 to 1.41) | 1.36 (1.21 to 1.53) |
2004–05 | 3.4 | 1.01 (0.62 to 1.40) | 1.36 (1.21 to 1.54) | 3.6 | 1.22 (0.82 to 1.62) | 1.42 (1.27 to 1.60) |
2005–06 | 3.5 | 1.04 (0.64 to 1.44) | 1.35 (1.20 to 1.52) | 3.6 | 1.05 (0.64 to 1.45) | 1.35 (1.20 to 1.51) |
2006–07 | 3.7 | 0.94 (0.54 to 1.35) | 1.31 (1.17 to 1.47) | 3.7 | 1.01 (0.59 to 1.42) | 1.32 (1.17 to 1.47) |
2007–08 | 3.7 | 0.62 (0.20 to 1.03) | 1.19 (1.06 to 1.34) | 3.7 | 1.02 (0.61 to 1.44) | 1.33 (1.18 to 1.49) |
Girls | ||||||
1997–98 | 0.7 | 0.31 (0.13 to 0.48) | 1.58 (1.21 to 2.06) | 0.8 | 0.36 (0.18 to 0.55) | 1.65 (1.27 to 2.13) |
1998–99 | 0.7 | 0.36 (0.19 to 0.53) | 1.78 (1.35 to 2.36) | 0.8 | 0.33 (0.16 to 0.50) | 1.72 (1.30 to 2.28) |
1999–00 | 0.7 | 0.29 (0.12 to 0.47) | 1.57 (1.19 to 2.06) | 0.8 | 0.38 (0.19 to 0.56) | 1.70 (1.31 to 2.21) |
2000–01 | 0.7 | 0.32 (0.14 to 0.50) | 1.61 (1.23 to 2.10) | 0.8 | 0.37 (0.19 to 0.56) | 1.69 (1.30 to 2.19) |
2001–02 | 0.8 | 0.36 (0.18 to 0.55) | 1.69 (1.30 to 2.21) | 0.8 | 0.49 (0.30 to 0.68) | 1.94 (1.49 to 2.52) |
2002–03 | 0.9 | 0.35 (0.15 to 0.55) | 1.55 (1.21 to 1.99) | 0.9 | 0.50 (0.29 to 0.70) | 1.79 (1.41 to 2.29) |
2003–04 | 1.0 | 0.51 (0.30 to 0.72) | 1.80 (1.41 to 2.29) | 1.0 | 0.43 (0.21 to 0.64) | 1.57 (1.25 to 1.98) |
2004–05 | 1.1 | 0.57 (0.35 to 0.78) | 1.83 (1.44 to 2.31) | 1.1 | 0.63 (0.41 to 0.85) | 1.93 (1.53 to 2.44) |
2005–06 | 1.1 | 0.48 (0.26 to 0.70) | 1.64 (1.30 to 2.06) | 1.1 | 0.61 (0.39 to 0.84) | 1.86 (1.48 to 2.36) |
2006–07 | 1.1 | 0.69 (0.45 to 0.92) | 1.97 (1.56 to 2.48) | 1.1 | 0.67 (0.44 to 0.90) | 1.96 (1.55 to 2.48) |
2007–08 | 1.2 | 0.63 (0.38 to 0.87) | 1.74 (1.40 to 2.18) | 1.1 | 0.75 (0.51 to 0.98) | 2.06 (1.63 to 2.60) |
Note: CI = confidence interval, RD = risk difference, RR = relative risk.
Data are grouped from December to November of the following year (e.g., 1997–98 refers to Dec. 1, 1997, to Nov. 30, 1998).
Children born in any month of the year who received a diagnosis of or treatment for attention-deficit/hyperactivity disorder.
χ2 tests for heterogeneity of relative risk across yearly strata. Among boys, χ2 = 8.3 (p = 0.6) for diagnosis and χ2 = 7.6 (p = 0.7) for treatment; among girls, χ2 = 3.7 (p > 0.9) for diagnosis and χ2 = 5.1 (p = 0.9) for treatment.